Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial

This project aims to compare the changes in the urinary quality of life (QoL) following focal high dose-rate brachytherapy (HDR-BT) boost to stereotactic ablative radiotherapy (SABR), compared to standard whole gland HDR-BT boost, in the treatment of men diagnosed with intermediate- and high-risk prostate cancer, with have an identifiable DIL on mpMRI.

Trial Details

NCT ID
NCT07300566
Phase
NA
Sponsor
Joelle Helou
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Standard Arm: Whole Gland High Dose Rate Brachytherapy Boost
  • Experimental Arm: Focal High Dose Rate Brachytherapy Boost
Locations (sample)
  • London, Ontario, Canada|42.98339,-81.23304

Key Eligibility Criteria

  • Histologically confirmed diagnosis of adenocarcinoma of the prostate
  • Eastern Co-Operative Oncology Group (ECOG) 0-2
  • Intermediate and high-risk disease with localized unfavorable features:
  • defined as clinical stage tumor cT1 or cT2a, International Society of Urological Pathology (ISUP) grade group 2-4 in less than or equal to 50% of t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →